160 related articles for article (PubMed ID: 2758415)
41. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
Chen VJ; Bewley JR; Andis SL; Schultz RM; Iversen PW; Shih C; Mendelsohn LG; Seitz DE; Tonkinson JL
Br J Cancer; 1998; 78 Suppl 3(Suppl 3):27-34. PubMed ID: 9717988
[TBL] [Abstract][Full Text] [Related]
42. Mammalian glycinamide ribonucleotide transformylase. Kinetic mechanism and associated de novo purine biosynthetic activities.
Caperelli CA
J Biol Chem; 1989 Mar; 264(9):5053-7. PubMed ID: 2925682
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of the synthesis of glycoproteins and induction of the differentiation of HL-60 promyelocytic leukemia cells by 6-methylmercaptopurine ribonucleoside.
Sokoloski JA; Sartorelli AC
Cancer Res; 1987 Dec; 47(23):6283-7. PubMed ID: 3479242
[TBL] [Abstract][Full Text] [Related]
44. Role of membrane-associated folate binding protein in the cytotoxicity of antifolates in KB, IGROV1, and L1210A cells.
Schultz RM; Andis SL; Shackelford KA; Gates SB; Ratnam M; Mendelsohn LG; Shih C; Grindey GB
Oncol Res; 1995; 7(2):97-102. PubMed ID: 7579732
[TBL] [Abstract][Full Text] [Related]
45. Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implications of inhibiting 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase to ampk activation and antitumor activity.
Mitchell-Ryan S; Wang Y; Raghavan S; Ravindra MP; Hales E; Orr S; Cherian C; Hou Z; Matherly LH; Gangjee A
J Med Chem; 2013 Dec; 56(24):10016-10032. PubMed ID: 24256410
[TBL] [Abstract][Full Text] [Related]
46. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
[TBL] [Abstract][Full Text] [Related]
47. Growth-inhibitory effects of 5,10-dideazatetrahydrofolic acid on variant murine L1210 and human CCRF-CEM leukemia cells with different membrane-transport characteristics for (anti)folate compounds.
Jansen G; Westerhof GR; Kathmann I; Rijksen G; Schornagel JH
Cancer Chemother Pharmacol; 1991; 28(2):115-7. PubMed ID: 2060081
[TBL] [Abstract][Full Text] [Related]
48. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.
Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G
Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196
[TBL] [Abstract][Full Text] [Related]
49. Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis.
Tonkinson JL; Marder P; Andis SL; Schultz RM; Gossett LS; Shih C; Mendelsohn LG
Cancer Chemother Pharmacol; 1997; 39(6):521-31. PubMed ID: 9118464
[TBL] [Abstract][Full Text] [Related]
50. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol.
Mendelsohn LG; Shih C; Schultz RM; Worzalla JF
Invest New Drugs; 1996; 14(3):287-94. PubMed ID: 8958184
[TBL] [Abstract][Full Text] [Related]
51. Design, synthesis, and biological evaluation of 10-methanesulfonyl-DDACTHF, 10-methanesulfonyl-5-DACTHF, and 10-methylthio-DDACTHF as potent inhibitors of GAR Tfase and the de novo purine biosynthetic pathway.
Cheng H; Chong Y; Hwang I; Tavassoli A; Zhang Y; Wilson IA; Benkovic SJ; Boger DL
Bioorg Med Chem; 2005 May; 13(10):3577-85. PubMed ID: 15848770
[TBL] [Abstract][Full Text] [Related]
52. The human glycinamide ribonucleotide transformylase domain: purification, characterization, and kinetic mechanism.
Caperelli CA; Giroux EL
Arch Biochem Biophys; 1997 May; 341(1):98-103. PubMed ID: 9143358
[TBL] [Abstract][Full Text] [Related]
53. Novel pyrrolo[2,3-d]pyrimidine antifolate TNP-351: cytotoxic effect on methotrexate-resistant CCRF-CEM cells and inhibition of transformylases of de novo purine biosynthesis.
Itoh F; Russello O; Akimoto H; Beardsley GP
Cancer Chemother Pharmacol; 1994; 34(4):273-9. PubMed ID: 8033293
[TBL] [Abstract][Full Text] [Related]
54. Dual effects of pyrazofurin and 3-deazauridine upon pyrimidine and purine biosynthesis in mouse L1210 leukemia.
Sant ME; Lyons SD; Kemp AJ; McClure LK; Szabados E; Christopherson RI
Cancer Res; 1989 May; 49(10):2645-50. PubMed ID: 2713848
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of 2-desamino-2-methyl-10-propagyl-5,8-dideazafolic acid cytotoxicity by 5,10-dideazatetrahydrofolate in L1210 cells with decrease in DNA fragmentation and deoxyadenosine triphosphate pools.
Kwok JB; Tattersall MH
Biochem Pharmacol; 1991 Jul; 42(3):507-13. PubMed ID: 1859463
[TBL] [Abstract][Full Text] [Related]
56. Role of membrane folate-binding protein in the cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cell lines in vitro.
Sen S; Erba E; D'Incalci M; Bottero F; Canevari S; Tomassetti A
Br J Cancer; 1996 Feb; 73(4):525-30. PubMed ID: 8595169
[TBL] [Abstract][Full Text] [Related]
57. Synthesis and biological activity of an acyclic analogue of 5,6,7,8-tetrahydrofolic acid, N-[4-[[3-(2,4-diamino-1,6-dihydro-6-oxo-5- pyrimidinyl)propyl]amino]-benzoyl]-L-glutamic acid.
Kelley JL; McLean EW; Cohn NK; Edelstein MP; Duch DS; Smith GK; Hanlon MH; Ferone R
J Med Chem; 1990 Feb; 33(2):561-7. PubMed ID: 2299624
[TBL] [Abstract][Full Text] [Related]
58. Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis.
Ray MS; Muggia FM; Leichman CG; Grunberg SM; Nelson RL; Dyke RW; Moran RG
J Natl Cancer Inst; 1993 Jul; 85(14):1154-9. PubMed ID: 8320744
[TBL] [Abstract][Full Text] [Related]
59. A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.
Laohavinij S; Wedge SR; Lind MJ; Bailey N; Humphreys A; Proctor M; Chapman F; Simmons D; Oakley A; Robson L; Gumbrell L; Taylor GA; Thomas HD; Boddy AV; Newell DR; Calvert AH
Invest New Drugs; 1996; 14(3):325-35. PubMed ID: 8958188
[TBL] [Abstract][Full Text] [Related]
60. The stereospecific cytotoxic potency of (6R) and (6S)-5,10- dideazatetrahydrofolate correlates with cellular folylpolyglutamate synthetase levels.
Lehman NL
Biochimie; 1995; 77(4):273-8. PubMed ID: 8589057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]